Certara (NASDAQ:CERT) Shares Gap Up to $13.42

Certara, Inc. (NASDAQ:CERTGet Rating)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $13.42, but opened at $13.89. Certara shares last traded at $13.55, with a volume of 5,965 shares changing hands.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Credit Suisse Group assumed coverage on shares of Certara in a research report on Wednesday, August 24th. They issued an “outperform” rating and a $22.00 price objective for the company. SVB Leerink decreased their price objective on shares of Certara from $29.00 to $26.00 and set an “outperform” rating for the company in a research report on Wednesday, August 10th. Piper Sandler decreased their price objective on shares of Certara from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, August 10th. Barclays decreased their price objective on shares of Certara from $24.00 to $21.00 and set an “overweight” rating for the company in a research report on Wednesday, August 17th. Finally, Berenberg Bank assumed coverage on shares of Certara in a research report on Thursday, September 8th. They issued a “buy” rating and a $23.00 price objective for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $24.00.

Certara Trading Down 1.2 %

The company’s fifty day moving average is $18.40 and its two-hundred day moving average is $19.57. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.51 and a current ratio of 3.51. The company has a market cap of $2.09 billion, a price-to-earnings ratio of -217.67, a P/E/G ratio of 0.84 and a beta of 1.27.

Certara (NASDAQ:CERTGet Rating) last issued its quarterly earnings results on Tuesday, August 9th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a positive return on equity of 4.26% and a negative net margin of 3.14%. The business had revenue of $82.00 million during the quarter, compared to analyst estimates of $85.46 million. During the same quarter last year, the company posted $0.03 EPS. Certara’s quarterly revenue was up 17.0% compared to the same quarter last year. On average, research analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

Insider Transactions at Certara

In other news, insider Patrick F. Smith sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $17.71, for a total transaction of $177,100.00. Following the sale, the insider now owns 78,490 shares of the company’s stock, valued at approximately $1,390,057.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Patrick F. Smith sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $17.71, for a total transaction of $177,100.00. Following the sale, the insider now owns 78,490 shares of the company’s stock, valued at approximately $1,390,057.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stephen M. Mclean acquired 20,000 shares of the company’s stock in a transaction dated Friday, August 19th. The shares were purchased at an average cost of $16.32 per share, for a total transaction of $326,400.00. Following the purchase, the director now directly owns 42,000 shares in the company, valued at $685,440. The disclosure for this purchase can be found here. Insiders have sold 6,196,893 shares of company stock valued at $107,705,300 in the last 90 days. 4.02% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Certara

Institutional investors have recently added to or reduced their stakes in the stock. First Horizon Advisors Inc. grew its stake in Certara by 9,193.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 1,487 shares of the company’s stock valued at $32,000 after acquiring an additional 1,471 shares during the period. Benjamin Edwards Inc. grew its stake in Certara by 9,338.1% in the 1st quarter. Benjamin Edwards Inc. now owns 1,982 shares of the company’s stock valued at $43,000 after acquiring an additional 1,961 shares during the period. Hardy Reed LLC acquired a new stake in Certara in the 1st quarter valued at $89,000. Captrust Financial Advisors lifted its holdings in Certara by 135.8% in the 1st quarter. Captrust Financial Advisors now owns 4,628 shares of the company’s stock valued at $99,000 after purchasing an additional 2,665 shares in the last quarter. Finally, MetLife Investment Management LLC purchased a new position in Certara in the 1st quarter valued at $111,000. Institutional investors and hedge funds own 77.42% of the company’s stock.

About Certara

(Get Rating)

Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.

Featured Stories

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.